共 50 条
Epigenetic biomarkers in skin cancer
被引:48
|作者:
Greenberg, Edward S.
[1
]
Chong, Kelly K.
[1
]
Huynh, Kelly T.
[1
]
Tanaka, Ryo
[1
]
Hoon, Dave S. B.
[1
]
机构:
[1] St Johns Hlth Ctr, John Wayne Canc Inst, Dept Mol Oncol, Santa Monica, CA 90404 USA
基金:
美国国家卫生研究院;
关键词:
Epigenetics;
Biomarker;
Methylation;
MicroRNA;
Melanoma;
Prognosis;
ISLAND METHYLATOR PHENOTYPE;
MELANOMA-CELL PROLIFERATION;
ABERRANT DNA METHYLATION;
TUMOR-SUPPRESSOR GENES;
REAL-TIME PCR;
DOWN-REGULATION;
CUTANEOUS MELANOMA;
PROMOTER HYPERMETHYLATION;
CIRCULATING MICRORNAS;
PERIPHERAL-BLOOD;
D O I:
10.1016/j.canlet.2012.01.020
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Epigenetic aberrations have been associated with cutaneous melanoma tumorigenesis and progression including dysregulated DNA gene promoter region methylation, histone modification, and microRNA. Several of these major epigenetic aberrations have been developed into biomarkers. Epigenetic biomarkers can be detected in tissue and in blood as circulating DNA in melanoma patients. There is strong evidence that biomarkers in cutaneous melanoma will have an important role as companions to therapeutics and overall patient management. Important progress has been made in epigenetic melanoma biomarker development and verification of clinical utility, and this review discusses some of the key current developments and existing challenges. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:170 / 177
页数:8
相关论文